Tag: #Global Trends

Key Development The FDA has approved WELTRUZA, Teva's once-monthly subcutaneous extended-release olanzapine for adults with schizophrenia. Its significance is not... Read more

Key Development Two months after Zenbexus won accelerated FDA approval on the strength of minimal residual disease, Bristol Myers Squibb... Read more

Key Development Biohub, the U.S. Department of Energy, NIH, Meta, Google DeepMind and Isomorphic Labs are assembling roughly $1.8 billion... Read more

Key Development AI drug development is moving beyond molecule design toward a more expensive bottleneck: predicting whether an experimental medicine... Read more

Key Development Just one day after VAX-31 met all primary endpoints in the pivotal OPUS-1 Phase 3 trial, Vaxcyte priced... Read more

ARRIVENT’S PHASE 3 FURVENT FAILURE: WHY STRONG TUMOR RESPONSES ARE NO LONGER ENOUGH TO WIN THE LUNG CANCER DRUG RACE... Read more

Key Development Becton Dickinson is becoming part of a broader rethink of medical-device manufacturing: products that look like commodities —... Read more

Key Development Eli Lilly has expanded its 2025 collaboration with Gate Bioscience, adding one new target and an option for... Read more

EPCORITAMAB + R-CHOP CUTS THE RISK OF PROGRESSION OR DEATH BY 51%: BISPECIFICS ARE MOVING FROM “SALVAGE” TO FRONTLINE DLBCL... Read more